21 CFR 211.84
Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.84: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under 21 CFR 211.84?
- 3 DSRV articles cite 21 CFR 211.84. Enforcement cases behind them: FDA Warning Letter CMS Case 732115 to ABS Corporation, July 23, 2026; FDA press announcement, FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight, May 6, 2026, with Commissioner Marty Makary's remarks at the FDLI Annual Conference; about 46 one-day assessments completed as of late April 2026; FDA Warning Letter 320-26-60 (case 721592) to Chemco Corporation, April 7, 2026, following an August 11 to 22, 2025 inspection of its Miami Lakes, Florida facility. Inspection exposure across them: 2 high, 1 moderate.
- What does DSRV recommend for 21 CFR 211.84?
- From the newest article (A Quality Unit That Averaged Away Its Own OOS Failures): The decisive control is whether the quality system forces failing data to be investigated before specifications, retest logic, or batch disposition can be changed. DSRV is decision support, not legal advice; verify against the official source each article names.
- 4 min readHigh exposurecited as a tag
A Quality Unit That Averaged Away Its Own OOS Failures
FDA's July 2026 warning letter to ABS Corporation shows a Quality Unit that averaged out failing assay results, handwrote higher specification limits onto batch records during validation, and released product made with a raw material that had already failed retesting. The pattern is not sloppy paperwork. It is a Quality Unit deciding the answer before the test ran.
- Case
- FDA Warning Letter CMS Case 732115 to ABS Corporation, July 23, 2026.
- DSRV take
- The decisive control is whether the quality system forces failing data to be investigated before specifications, retest logic, or batch disposition can be changed.
- 5 min readModerate exposurecited as a tag
FDA's 1-Day Inspection Pilot Changes Inspection Readiness
FDA's 1-day inspection pilot and AI-assisted risk ranking change what inspection readiness means for quality teams: less time to recover, more pressure on records that can stand on their own.
- Case
- FDA press announcement, FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight, May 6, 2026, with Commissioner Marty Makary's remarks at the FDLI Annual Conference; about 46 one-day assessments completed as of late April 2026.
- DSRV take
- A one-day assessment punishes performative readiness and rewards systems that stay organized without rehearsal, so inspection readiness has to be engineered into the daily system rather than staged for the visit.
- 6 min readHigh exposurecited as a tag
FDA Tied Residue, Cleaning Validation, and Component Controls at Chemco
FDA's April 2026 Chemco warning letter links visible residue, missing cleaning validation for shared equipment, and inadequate incoming component identity testing into one quality-system control failure.
- Case
- FDA Warning Letter 320-26-60 (case 721592) to Chemco Corporation, April 7, 2026, following an August 11 to 22, 2025 inspection of its Miami Lakes, Florida facility.
- DSRV take
- When residue, missing validation, and weak identity testing appear in one facility, FDA stops scoring individual gaps and asks whether the quality system can detect and correct risk before the investigator does, which is why disconnected lane-by-lane CAPAs fail in these cases.
Pressure-test your evidence before an inspector reads it
Bring the document that has to hold up under 21 CFR 211.84. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.